Candel Therapeutics Inc
NASDAQ:CADL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Candel Therapeutics Inc
NASDAQ:CADL
|
US |
|
G
|
Gama Management and Clearing Ltd
TASE:GMA
|
IL |
|
Quadient SA
PAR:QDT
|
FR |
|
Dharma Satya Nusantara Tbk PT
IDX:DSNG
|
ID |
|
Samindo Resources Tbk PT
IDX:MYOH
|
ID |
|
Altium Ltd
ASX:ALU
|
AU |
|
Marzocchi Pompe SpA
MIL:MARP
|
IT |
|
A
|
APS Energia SA
WSE:APE
|
PL |
|
S
|
Sunex SA
WSE:SNX
|
PL |
Candel Therapeutics Inc
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The company is headquartered in Needham, Massachusetts and currently employs 50 full-time employees. The company went IPO on 2021-07-27. The firm is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The firm also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The company is headquartered in Needham, Massachusetts and currently employs 50 full-time employees. The company went IPO on 2021-07-27. The firm is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The firm also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.
